Form 4: MaxCyte EVP Thomas M. Ross Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., exercised stock options and sold shares of common stock on August 1st and 2nd, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Thomas M. Ross, the EVP of Global Sales at MaxCyte, Inc., engaged in transactions involving the company's stock on August 1st and 2nd, 2024.
- These transactions involved the exercise of employee stock options and the subsequent sale of common stock.
- The exercises and sales were conducted under a Rule 10b5-1 trading plan adopted on March 19, 2024.
- On August 1st, Ross exercised options to acquire 15,476 shares at a price of $1.641 per share and sold the same amount at a weighted average price of $4.54.
- On August 2nd, Ross exercised options to acquire 17,857 shares at a price of $1.641 per share and sold the same amount at a weighted average price of $4.361.
- Following these transactions, Ross directly owns 25,000 shares of common stock.
- After the transactions, Ross holds 17,858 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions were pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance of the company.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry to assess company health and management confidence.
- Comparing the frequency and size of insider sales to those of executives at comparable biotech companies like CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine can provide context.
- The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, and many executives at publicly traded companies utilize such plans.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of adoption of Rule 10b5-1 trading plan. |
| 08/01/2024 | Date of first reported transaction (option exercise and sale). |
| 08/02/2024 | Date of second reported transaction (option exercise and sale). |
| 08/05/2024 | Date of Form 4 filing. |
| 01/20/2030 | Expiration date of Employee Stock Options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.